Four Crucial Questions about the Humira Biosimilar Price War

This month, nine biosimilar versions of adalimumab launched in the U.S. market. As I predicted in 2021, some products launched with list prices that are only slightly lower than Humira’s list price, while others are trying to tempt payers and pharmacy benefit manages (PBMs) with deep list price discounts.